Cat.#: ASSD-141
| Description | MTT is a tetrazolium dye that is frequently employed in experiments to measure the rate of cell proliferation or growth. When MTT is introduced into living cells, it undergoes a chemical transformation facilitated by certain enzymes called NAD(P)H-dependent cellular oxidoreductases, leading to the production of formazan which is a bluish or purplish insoluble substance. |
| Synonyms | Thiazolyl blue tetrazolium bromide |
| Size | 500 mg, 1 g |
| Applications | For used quantitation of cell viability and cell proliferation where the color intensity can be measured colormetrically (at 540 or 570 nM). |
| Chemical Name | 3-(4,5-dimethyl-1,3-thiazol-2-yl)-2,5-diphenyl-2H-tetrazol-3-ium bromide |
| Molecule Weight | 414.32 |
| Molecular formula | C18H16N5SBr |
| CAS Number | 298-93-1 |
| PubChem identifier | 64965 |
| MDL Number | MFCD00011964 |
| Purity | >97% |
| Solubility | Soluble in water (5 mg/ml) |
| Storage | Store at -20° C |
| Shipping | Shipped at 4°C |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-226 | Antifade Fluorescence Mounting Medium (hard set) (AC226) | 10 mL | inquiry |
| ASSD-206 | Eosine-5-isothiocyanate (AC206) | 50 mg | inquiry |
| ASSD-124 | Fluorescent β2 antagonist [(S)-propranolol-green] (AC124) | 500 μg | inquiry |
| ASSD-128 | Fluorescent M3 antagonist [pirenzepine] (AC128) | 50 μg | inquiry |
| ASSD-212 | 5(6)-Carboxy-2′,7′-dichlorofluorescein diacetate N-succinimidyl ester (AC212) | 25 mg | inquiry |
| ASSD-200 | Ethylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[3-difluoromethyl-4-phosphoanilinamidosuccinic Acid] Diamide (AC200) | 500 μg | inquiry |
| ASSD-130 | Calcein-AM (AC130) | 1 mg | inquiry |
| ASSD-110 | Picro Sirius Red Stain Kit (AC110) | 1 kit, 100 tests | inquiry |
| ASSD-105 | Hoechst 33342 (AC105) | 10 mg, 100 mg | inquiry |
| ASSD-123 | Fluorescent β2 antagonist [(S)-propranolol-red] (AC123) | 500 μg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.